Develop therapies based on induced mesenchymal stem cells (iMSC). Focus on treating solid tumors and autoimmune conditions. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Our checks did not surface a specific strength to highlight here.
A loss of $14.1M against $0 in annual sales.
The stock sits at $0.04. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.6 times as much as the market average. Big rallies — and big drops — can both happen fast.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the growth trend, the revenue breakdown, the price history.